Celgene 'determined to fight' after second NICE Abraxane no
This article was originally published in Scrip
Executive Summary
Celgene has said it won't give up on UK market access without a fight, after NICE issued its second draft guidance rejecting the company's pancreatic cancer drug Abraxane (nab-paclitaxel).